Evolus Statistics
Total Valuation
Evolus has a market cap or net worth of $550.86 million. The enterprise value is $670.49 million.
| Market Cap | 550.86M |
| Enterprise Value | 670.49M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolus has 66.05 million shares outstanding. The number of shares has increased by 2.34% in one year.
| Current Share Class | 66.05M |
| Shares Outstanding | 66.05M |
| Shares Change (YoY) | +2.34% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 11.05% |
| Owned by Institutions (%) | 62.53% |
| Float | 50.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 192.61 |
| PS Ratio | 1.67 |
| Forward PS | 1.47 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.70
| Current Ratio | 1.70 |
| Quick Ratio | 1.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.15 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.40% |
| Return on Invested Capital (ROIC) | -9.54% |
| Return on Capital Employed (ROCE) | -12.51% |
| Weighted Average Cost of Capital (WACC) | 10.78% |
| Revenue Per Employee | $904,251 |
| Profits Per Employee | -$98,094 |
| Employee Count | 350 |
| Asset Turnover | 1.33 |
| Inventory Turnover | 3.13 |
Taxes
In the past 12 months, Evolus has paid $654,000 in taxes.
| Income Tax | 654,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.49% in the last 52 weeks. The beta is 1.36, so Evolus's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | +39.49% |
| 50-Day Moving Average | 6.55 |
| 200-Day Moving Average | 5.90 |
| Relative Strength Index (RSI) | 77.55 |
| Average Volume (20 Days) | 971,619 |
Short Selling Information
The latest short interest is 5.91 million, so 8.94% of the outstanding shares have been sold short.
| Short Interest | 5.91M |
| Short Previous Month | 6.02M |
| Short % of Shares Out | 8.94% |
| Short % of Float | 11.77% |
| Short Ratio (days to cover) | 7.11 |
Income Statement
In the last 12 months, Evolus had revenue of $316.49 million and -$34.33 million in losses. Loss per share was -$0.53.
| Revenue | 316.49M |
| Gross Profit | 211.21M |
| Operating Income | -20.61M |
| Pretax Income | -33.68M |
| Net Income | -34.33M |
| EBITDA | -9.78M |
| EBIT | -18.67M |
| Loss Per Share | -$0.53 |
Balance Sheet
The company has $45.17 million in cash and $164.80 million in debt, with a net cash position of -$119.63 million or -$1.81 per share.
| Cash & Cash Equivalents | 45.17M |
| Total Debt | 164.80M |
| Net Cash | -119.63M |
| Net Cash Per Share | -$1.81 |
| Equity (Book Value) | -30.90M |
| Book Value Per Share | -0.47 |
| Working Capital | 68.81M |
Cash Flow
In the last 12 months, operating cash flow was -$15.38 million and capital expenditures -$2.90 million, giving a free cash flow of -$18.28 million.
| Operating Cash Flow | -15.38M |
| Capital Expenditures | -2.90M |
| Depreciation & Amortization | 8.89M |
| Net Borrowing | 9.98M |
| Free Cash Flow | -18.28M |
| FCF Per Share | -$0.28 |
Margins
Gross margin is 66.74%, with operating and profit margins of -6.51% and -10.85%.
| Gross Margin | 66.74% |
| Operating Margin | -6.51% |
| Pretax Margin | -10.64% |
| Profit Margin | -10.85% |
| EBITDA Margin | -3.09% |
| EBIT Margin | -5.90% |
| FCF Margin | n/a |
Dividends & Yields
Evolus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.34% |
| Shareholder Yield | -2.34% |
| Earnings Yield | -6.49% |
| FCF Yield | -3.46% |
Analyst Forecast
The average price target for Evolus is $14.67, which is 75.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.67 |
| Price Target Difference | 75.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 15.83% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolus has an Altman Z-Score of -1.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.61 |
| Piotroski F-Score | 2 |